Cytosorbents Corporation (NASDAQ:CTSO ) Q2 2022 Earnings Conference Call August 2, 2022 4:30 PM ET Company Participants Amy Vogel – Investor Relations Phillip Chan – Chief Executive Officer Kathle

CytoSorbents (CTSO) Reports Q2 Loss, Lags Revenue Estimates

10:35pm, Tuesday, 02'nd Aug 2022 Zacks Investment Research
CytoSorbents (CTSO) delivered earnings and revenue surprises of -78.57% and 11.15%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
PRINCETON, N.J. , July 25, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using

Abbott (ABT) Q2 Earnings and Revenues Top Estimates

12:45pm, Wednesday, 20'th Jul 2022 Zacks Investment Research
Abbott (ABT) delivered earnings and revenue surprises of 31.19% and 8.67%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

3 Stocks Under $3 Insiders Are Aggressively Buying

11:45am, Monday, 13'th Jun 2022 Benzinga
The Nasdaq Composite dropped by more than 400 points on Friday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or co
The Nasdaq Composite dropped by more than 400 points on Friday. Investors, meanwhile, focused on some notable insider trades.
Insiders are buying these penny stocks. The post 10 Top Penny Stocks To Buy In June According To These Insiders Part 1 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.
Insiders are buying these penny stocks. The post 10 Top Penny Stocks To Buy In June According To These Insiders Part 1 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.
Cytosorbents Corporation (NASDAQ:CTSO ) Q1 2022 Earnings Conference Call May 3, 2022 4:30 PM ET Company Participants Terri Anne Powers - Vice President, Investor Relations & Corporate Communications P
Cytosorbents Corporation (CTSO) CEO Phillip Chan on Q4 2021 Results - Earnings Call Transcript
MONMOUTH JUNCTION, N.J., March 8, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, today…
MONMOUTH JUNCTION, N.J., Feb. 8, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report fourth quarter and full year 2021 operating and…
MONMOUTH JUNCTION, N.J., Feb. 8, 2022 /PRNewswire/ --  CytoSorbents Corporation  (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surge
CytoSorbents Corp (NASDAQ: CTSO ) reported preliminary Q4 FY21 revenue of approximately $10.8 million , better than the consensus of $9.58 million. It reported revenue of $12.0 million in Q4 2020. The company expects blended product gross margins to be approximately 80% for Q4 Full story available on Benzinga.com
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE